Drug Profile

SYD 003

Alternative Names: SYD-003

Latest Information Update: 12 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Synovo
Class
Mechanism of Action Immunomodulators; P38 mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity No
Available For Licensing Yes

12 Sep 2023 Preclinical development of SYD 003 for Pancreatic cancer is ongoing in Germany (PO) (Synovo website, September 2023)
12 Sep 2023 SYD 003 is available for licensing as of 12 Sep 2023. https://synovo.com/innovation/
26 Jul 2016 Preclinical trials in Pancreatic cancer in Germany (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com